Liaison(s): Mark Johnson
MediciNova, Inc, a San Diego based biopharmaceutical company, was founded with the goal of acquiring and accelerating the global development and commercialization of innovative pharmaceutical products, with a focus on the U.S. market. Since its inception in 2000, and IPO on the Osaka Securities Exchange in 2005 and NASDAQ in 2006, the company has successfully in-licensed six clinical stage compounds. The company has focused its development efforts on two core assets, MN-221 for exacerbations of asthma and COPD, and MN-166 for neuropathic pain, drug addiction, and progressive multiple sclerosis. The MediciNova TMP was designed to assist the company’s business development team in furthering the development of core and non-core assets. This has been accomplished through conducting thorough market analyses for specific assets, including the current competitive landscape, conducting KOL surveys, identifying clinical differentiation parameters, developing revenue forecasts and financial models, and providing insight into the current market opportunities for the compounds of interest. Deliverables from the TMP will be used in MediciNova’s near term efforts to out-license and partner these assets for continued development.